GLP‑1 (Glucagon‑Like Peptide‑1) Dosing Protocol Summary
Glucagon‑Like Peptide‑1 (GLP‑1) receptor agonists are incretin‑based therapies used to improve glycemic control in type 2 diabetes mellitus and, in some formulations, to support weight management. These agents mimic endogenous GLP‑1 to enhance glucose‑dependent insulin secretion, suppress glucagon, slow gastric emptying, and increase satiety (GoodRx, 2025; Mayo Clinic, 2025). A key principle in dosing protocols is gradual titration: starting with low “initiation” doses to mitigate gastrointestinal side effects such as nausea and vomiting, followed by incremental increases at defined intervals until therapeutic or maintenance doses are reached (Straight HealthCare, 2025; DrOracle, 2025).
For example, semaglutide (Ozempic®) typically begins at 0.25 mg subcutaneously once weekly for four weeks and then is increased to 0.5 mg weekly, with further escalation to 1 mg or 2 mg weekly as needed (NCBI Bookshelf, 2022; Ozempic, 2025). Liraglutide (Victoza®) starts at 0.6 mg once daily, increasing to 1.2 mg and up to 1.8 mg daily based on response (Drugs.com, 2025; Mayo Clinic, 2025). Careful monitoring and individualized adjustments are essential, with clinical judgment guiding dose escalation based on efficacy and tolerability.
GLP‑1 Dosing Chart
| Agent | Starting Dose | Escalation | Maintenance/Max Dose |
|---|---|---|---|
| Semaglutide (Ozempic) | 0.25 mg weekly | Increase after 4 wk | 0.5 mg → 1 mg → 2 mg weekly (NCBI) |
| Liraglutide (Victoza) | 0.6 mg daily | Increase after 1 wk | 1.2 mg → 1.8 mg daily (NCBI) |
| Wegovy (semaglutide) | 0.25 mg weekly | Escalate every 4 wk | Up to 2.4 mg weekly (Wegovy) |
References (APA format):
Drugs.com. (2025). Liraglutide dosage.
GoodRx. (2025). GLP‑1 agonists comparison.
Mayo Clinic. (2025). Semaglutide dosing & usage.
NCBI Bookshelf. (2022). GLP‑1 receptor agonist dosing table.
Ozempic. (2025). Dosing schedule.
Straight HealthCare. (2025). GLP‑1 analog dosing chart.
